ImmunityAPNIPNCT07070180
Analysis of Psychoneuroimmunological Parameters of Health in Specific Population Groups in Slovakia
An observational study of Immunity and Cytokine Levels, run by Comenius University at 3 sites in Slovakia.
Trial summary
This study aims to investigate the links between psychological and biological immunity from the perspective of psychology, epidemiology, and immunology in a general population study sample as well as in a specific group of people in treatment for alcohol addiction. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Immunity, Cytokine Levels, Psychological Adaptation
- How many people
- 700 participants
- Where
- 3 sitesSlovakia
- Study dates
- 1 Jan 2024to 15 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: 'General Slovak Population Sample' will be selected from adult population aged 18-50 years living in Bratislava, Banská Bystrica and Košice regions. Participants were recruited through media promotion of the research. The study group was selected from the registered volunteers based on stratification by age and sex, with equal representation across the age groups 18-30, 31-40, and 41-50 years. The sample 'Individuals receiving inpatient treatment for alcohol addiction at the treatment facility' was selected from patients admitted at addiction treatment facility within 48 hours of their admission. The study sample included 100 volunteers aged 18-50 years.
Who may be able to join
- Age between 18 - 50 years
- Residency in the respective region for at least five years
- Consent to participate in the study
Who cannot join
- Individuals younger than 18 or older than 50 years
- Ongoing acute infectious disease on the day of testing
- Eligible individuals who do not provide informed consent
- Inclusion Criteria for the sample 'Individuals receiving inpatient treatment for alcohol addiction at the treatment facility':
- Age between 18 - 50 years
- Admission to treatment for alcohol addiction
Show all 11Show fewer
- Consent to participate in the study, Treatment completion
- Exclusion Criteria for the sample 'Individuals receiving inpatient treatment for alcohol addiction at the treatment facility':
- Individuals younger than 18 or older than 50 years
- Eligible individuals who do not provide informed consent
- Drop-out from alcohol addiction treatment
Trial locations and contacts
3 sites in 1 country.
Slovakia3 sites
Comenius University Bratislava, Faculty of Arts
Bratislava, 81102
Comenius University, Faculty of Medicine in Bratislava
Bratislava, 81108
Slovak Academy of Sciences, Institute of Neuroimmunology
Bratislava, 84510
About this study
This study aims to investigate the links between psychological and biological immunity from the perspective of psychology, epidemiology, and immunology in a general population study sample as well as in a specific group of people in treatment for alcohol addiction.
Read the detailed description
The study will explore the associations between the level of psychological immunity and the current psychological state of the participants, possible links between the level of psychological immunity in adulthood and adverse childhood experiences, and finally, the association between the psychological immunity and biological immunity expressed by the self- assessed perceived immune status and on a molecular level by quantity of cytokines and in a specific subgroup also by natural killer cells. All this will be studied in a sample of general population as well as in a specific group of people in treatment for alcohol addiction that was chosen based on the known adverse immune-related health effects of excessive alcohol consumption.
- Conditions
- Immunity, Cytokine Levels, Psychological Adaptation, Resilience, Positive Thinking, Sense of Control
- Keywords
- psychological immunity, biological immunity, psychoneuroimmunology
- Medical subject headings
- Self-Control, Fractures, Stress, Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| General Slovak population sample | Adults aged 18 to 50, with the upper age limit set to account for the natural decline in immune function beyond this age. A total of 600 participants were recruited from three regions: 300 from the Bratislava region, 150 from the Banská Bystrica region, and 150 from the Košice region. | |
| Individuals receiving inpatient treatment for alcohol addiction at the treatment facility | 100 participants aged 18 to 50 years who undergo psychological, epidemiological, and immunological assessments multiple time points - upon admission, during hospitalisation, and at the conclusion of treatment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome measure is the correlation between psychological immunity, current health status and cytokine levels as indicators of biological immune function.
The psychological instrument will consist of the Psychological immune competence inventory (PICI) to assess the psychological immunity.
Current health status will be assessed by the epidemiological instrument that will evaluate self-assessed immune status, overall, mental, and physical health, current long-term conditions, social, and economic status. Units of measure for the questionnaires is a score.
Cytokine secretion by immune cells will be tested using Bio-Plex ProTM Human Cytokine 17- plex assay according to the instructions of the manufacturer. For the analysis the blood plasma will be used. In each sample the following panel of cytokines will be analysed: G- CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β, TNF-α. Cytokine units of measure are picograms per milliliter.
Measured: At the time of study enrollment for Group 1, at the time of admission in treatment and after completion of 3 months of treatment for Group 2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2025
- Study start1 Jan 2024
- Primary completion15 Dec 2024
- Study completion15 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for ImmunityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 700 participants (actual)
Sponsor and investigators
- Lead sponsor
- Comenius University
- Sponsor type
- University, hospital or other
- Collaborators
- Slovak Academy of Sciences
- Responsible party
- Sponsor
- Investigators
- Alexandra Bražinová, prof., MD, PhD, Principal investigator, Comenius University, Faculty of Medicine in Bratislava
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07070180
- Sponsor's protocol ID
- APVV-22-0160
- Acronym
- APNIP
- Status last verified
- Feb 2026
- First submitted
- 18 May 2025
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Andersen BL, Farrar WB, Golden-Kreutz DM, Glaser R, Emery CF, Crespin TR, Shapiro CL, Carson WE 3rd. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol. 2004 Sep 1;22(17):3570-80. doi: 10.1200/JCO.2004.06.030.
PubMed 15337807Shields GS, Spahr CM, Slavich GM. Psychosocial Interventions and Immune System Function: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry. 2020 Oct 1;77(10):1031-1043. doi: 10.1001/jamapsychiatry.2020.0431.
PubMed 32492090Brydon L, Walker C, Wawrzyniak A, Whitehead D, Okamura H, Yajima J, Tsuda A, Steptoe A. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun. 2009 Feb;23(2):217-24. doi: 10.1016/j.bbi.2008.09.007. Epub 2008 Sep 20.
PubMed 18835437
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Psychoneuroimmunological Parameters of Health in Specific Population Groups in Slovakia
- ClinicalTrials.gov ID
- NCT07070180
- Acronym / sponsor ID
- APNIP / APVV-22-0160
- Conditions
- Immunity, Cytokine Levels, Psychological Adaptation, Resilience, Positive Thinking, Sense of Control
- Keywords
- psychological immunity, biological immunity, psychoneuroimmunology
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 700 participants (actual)
- Lead sponsor
- Comenius UniversityUniversity, hospital or other
- Collaborators
- Slovak Academy of Sciences
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 15 Dec 2024 (actual)
- Study completion
- 15 Dec 2025 (actual)
- First posted
- 17 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the links between psychological and biological immunity from the perspective of psychology, epidemiology, and immunology in a general population study sample as well as in a specific group of people in treatment for alcohol addiction.
Detailed description
The study will explore the associations between the level of psychological immunity and the current psychological state of the participants, possible links between the level of psychological immunity in adulthood and adverse childhood experiences, and finally, the association between the psychological immunity and biological immunity expressed by the self- assessed perceived immune status and on a molecular level by quantity of cytokines and in a specific subgroup also by natural killer cells. All this will be studied in a sample of general population as well as in a specific group of people in treatment for alcohol addiction that was chosen based on the known adverse immune-related health effects of excessive alcohol consumption.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| General Slovak population sample | – | –Adults aged 18 to 50, with the upper age limit set to account for the natural decline in immune function beyond this age. A total of 600 participants were recruited from three regions: 300 from the Bratislava region, 150 from the Banská Bystrica region, and 150 from the Košice region. |
| Individuals receiving inpatient treatment for alcohol addiction at the treatment facility | – | –100 participants aged 18 to 50 years who undergo psychological, epidemiological, and immunological assessments multiple time points - upon admission, during hospitalisation, and at the conclusion of treatment. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- 'General Slovak Population Sample' will be selected from adult population aged 18-50 years living in Bratislava, Banská Bystrica and Košice regions. Participants were recruited through media promotion of the research. The study group was selected from the registered volunteers based on stratification by age and sex, with equal representation across the age groups 18-30, 31-40, and 41-50 years. The sample 'Individuals receiving inpatient treatment for alcohol addiction at the treatment facility' was selected from patients admitted at addiction treatment facility within 48 hours of their admission. The study sample included 100 volunteers aged 18-50 years.
Key inclusion criteria (3 listed)
- Age between 18 - 50 years
- Residency in the respective region for at least five years
- Consent to participate in the study
Key exclusion criteria (11 listed)
- Individuals younger than 18 or older than 50 years
- Ongoing acute infectious disease on the day of testing
- Eligible individuals who do not provide informed consent
- Inclusion Criteria for the sample 'Individuals receiving inpatient treatment for alcohol addiction at the treatment facility':
- Age between 18 - 50 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The primary outcome measure is the correlation between psychological immunity, current health status and cytokine levels as indicators of biological immune function.
Time frame: At the time of study enrollment for Group 1, at the time of admission in treatment and after completion of 3 months of treatment for Group 2
The psychological instrument will consist of the Psychological immune competence inventory (PICI) to assess the psychological immunity. Current health status will be assessed by the epidemiological instrument that will evaluate self-assessed immune status, overall, mental, and physical health, current long-term conditions, social, and economic status. Units of measure for the questionnaires is a score. Cytokine secretion by immune cells will be tested using Bio-Plex ProTM Human Cytokine 17- plex assay according to the instructions of the manufacturer. For the analysis the blood plasma will be used. In each sample the following panel of cytokines will be analysed: G- CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β, TNF-α. Cytokine units of measure are picograms per milliliter.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
- Results publication: PubMed 15337807Andersen BL, Farrar WB, Golden-Kreutz DM, Glaser R, Emery CF, Crespin TR, Shapiro CL, Carson WE 3rd. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol. 2004 Sep 1;22(17):3570-80. doi: 10.1200/JCO.2004.06.030.
- Results publication: PubMed 32492090Shields GS, Spahr CM, Slavich GM. Psychosocial Interventions and Immune System Function: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry. 2020 Oct 1;77(10):1031-1043. doi: 10.1001/jamapsychiatry.2020.0431.
- Results publication: PubMed 18835437Brydon L, Walker C, Wawrzyniak A, Whitehead D, Okamura H, Yajima J, Tsuda A, Steptoe A. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun. 2009 Feb;23(2):217-24. doi: 10.1016/j.bbi.2008.09.007. Epub 2008 Sep 20.
- Information about the study published on the website of Comenius Uniiversity in Slovak languageLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Immunity
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingObservational study
Characterization of Adaptive Immune Responses to Oropouche Virus (OROV) Infection
Oropouche Infection
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Active, not recruitingEarly Phase 1
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
Influenza, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandra Bražinová, prof., MD, PhD principal investigator
Comenius University, Faculty of Medicine in Bratislava
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Immunity and Cytokine Levels, run by Comenius University at 3 sites in Slovakia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Slovakia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome measure is the correlation between psychological immunity, current health status and cytokine levels as indicators of biological immune function. (time frame: At the time of study enrollment for Group 1, at the time of admission in treatment and after completion of 3 months of treatment for Group 2). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07070180, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.